News

cardiologists heart doctors

The J-Valve System is associated with positive 10-year outcomes for patients with severe AR, according to new research out of China. It also performs well in patients with severe AS.

heart drugs with stethoscope

An experimental oral PCSK9 inhibitor is associated with LDL-C reductions that could prove to be a game-changer for patient care. 

SCAI has shared a new call to action as an observance of American Heart Month. The group is asking Congress to pass new pieces of legislation that could improve care for PAD patients and get important medical devices in the hands of interventional cardiologists.

Cerepak Detachable Coil Systems

Several detachable coil systems are being recalled due to a higher-than-expected failure to detach rate. Customers should not use them going forward.

the words "FDA recall" on a board

New Jersey-based Zydus Pharmaceuticals has recalled nearly 23,000 bottles of its icosapent ethyl capsules due to leakage issues that may have weakened their effectiveness. 

heart surgery surgeons

Survival rates are high for both men and women presenting with BAV disease, according to a new analysis of nearly 28,000 SAVR patients.

Open surgical bypass is the gold standard, but endovascular therapies may provide value for high-risk patients with long femoropopliteal lesions.

The cardiologist at the head of an influential CDC panel sees serious problems with modern vaccine policies. While many experts seem to disagree, one organization has jumped to his defense. 

money gavel court lawsuit legal judge judgement

The alleged scheme involved a series of diagnostic procedures that, according to the U.S. government, were not medically necessary. 

artificial intelligence money finance acquisition

Medtronic confirmed its decision in a statement, but did not provide any specific details. The deal was originally announced in May.

Harlan M. Krumholz, MD, Yale American College of Cardiology

The publication's current editor-in-chief is Valentin Fuster, MD, PhD. Harlan M. Krumholz, MD, will begin his five-year term in 2024.

The popular SGLT2 inhibitor, sold under the brand name Farxiga, is approved by the FDA to treat heart failure, type 2 diabetes and CKD. Recent data on its ability to affect the symptoms of heart failure patients have been inconsistent. 

Around the web

Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's  FDA 510(k)-pending photon-counting CT scanner.